[An eighteen-year study on phenylketonuria]

Wei-min Yu1, Li Xu, Xioa-wen Li

  • 1Department of Genetic and Metabolic Disease, China-Japan Friendship Hospital, China-Japan Friendship Institute of Clinical Medical Science, Beijing 100029, China. yuweim@public.bta.net.cn

Insights

Early diagnosis and treatment of phenylketonuria (PKU) with a low-phenylalanine diet lead to normal development. Tetrahydrobiopterin (BH4) deficiency also shows promising treatment outcomes in PKU patients.

Area of Science:

  • Biochemistry
  • Genetics
  • Neurology

Context:

  • Phenylketonuria (PKU) is a genetic disorder.
  • BH4 deficiency is another metabolic disorder affecting neurotransmitter synthesis.
  • Long-term PKU studies are crucial for understanding disease progression and treatment efficacy.

Purpose:

  • To analyze the diagnosis and treatment outcomes of PKU patients.
  • To investigate BH4 deficiency in Chinese populations.
  • To correlate genotype with intellectual phenotype in PKU.

Summary:

  • A study of 603 PKU patients from 1984-2002 showed early treatment leads to normal development, while late treatment improves symptoms.
  • 369 patients with hyperphenylalaninemia (HPA) were analyzed for BH4 deficiency, identifying 22 cases with specific mutations and successful treatment outcomes.
  • EEG and MRI revealed significant abnormalities in untreated PKU patients, which decreased after dietary intervention.
  • Genotype-intellectual phenotype correlation in 29 classical PKU patients indicated a strong association.

Impact:

  • Highlights the critical importance of early PKU detection and intervention.
  • Provides insights into BH4 deficiency genetics and treatment in China.
  • Demonstrates the effectiveness of dietary management and potential therapeutic options for PKU and related disorders.
  • Establishes a link between genetic makeup and cognitive outcomes in PKU.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...